14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $11.01 $14.21 Friday, 3rd May 2024 IOVA stock ended at $13.63. This is 5.82% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.36% from a day low at $13.30 to a day high of $13.88.
90 days $7.62 $18.33
52 weeks $3.21 $18.33

Historical Iovance Biotherapeutics, Inc. prices

Date Open High Low Close Volume
Feb 22, 2024 $16.37 $16.93 $14.86 $15.94 34 547 078
Feb 21, 2024 $12.10 $16.05 $12.09 $15.77 63 568 661
Feb 20, 2024 $11.65 $13.41 $11.31 $12.03 58 382 064
Feb 16, 2024 $9.65 $10.43 $8.88 $9.15 13 804 862
Feb 15, 2024 $9.73 $10.16 $9.64 $9.87 5 577 269
Feb 14, 2024 $9.48 $9.64 $9.20 $9.55 3 621 528
Feb 13, 2024 $9.45 $9.58 $8.96 $9.16 6 770 224
Feb 12, 2024 $9.30 $9.99 $9.30 $9.95 7 927 511
Feb 09, 2024 $8.82 $9.34 $8.71 $9.18 7 106 013
Feb 08, 2024 $8.08 $8.87 $7.96 $8.68 6 070 965
Feb 07, 2024 $8.17 $8.44 $7.99 $8.07 5 401 916
Feb 06, 2024 $7.90 $8.20 $7.68 $8.16 4 689 744
Feb 05, 2024 $7.76 $7.98 $7.62 $7.92 3 110 957
Feb 02, 2024 $7.80 $7.98 $7.60 $7.90 5 522 650
Feb 01, 2024 $7.85 $8.27 $7.67 $8.06 4 349 743
Jan 31, 2024 $7.78 $8.22 $7.71 $7.73 4 237 239
Jan 30, 2024 $7.60 $8.23 $7.60 $7.84 4 317 112
Jan 29, 2024 $7.60 $8.36 $7.34 $8.30 6 791 171
Jan 26, 2024 $7.70 $8.07 $7.58 $7.59 5 181 234
Jan 25, 2024 $7.75 $7.88 $7.44 $7.64 6 251 935
Jan 24, 2024 $7.86 $8.04 $7.62 $7.65 4 518 002
Jan 23, 2024 $8.26 $8.42 $7.44 $7.78 6 866 230
Jan 22, 2024 $7.86 $8.25 $7.81 $8.08 5 445 258
Jan 19, 2024 $7.94 $7.96 $7.60 $7.78 5 044 429
Jan 18, 2024 $8.15 $8.25 $7.80 $7.94 5 863 631
Click to get the best stock tips daily for free!

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics. Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers... IOVA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT